--- SMARTEST Trial---
Condition:   Mesothelioma, Malignant Interventions:   Drug: Cyclophosphamide;   Drug: Tremelimumab;   Drug: Durvalumab Sponsors:   University Health Network, Toronto;   OICR Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 19, 2022 Category: Research Source Type: clinical trials

Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin
Conditions:   Malignant Pleural Mesotheliomas (Mpm);   Malignant Pleural Effusions (Mpe);   Epithelial Tumors, Malignant;   Pleural Effusions, Malignant;   Mesothelin (Msln) Interventions:   Procedure: Cytoreductive surgery;   Drug: LMB-100;   Diagnostic Test: Immunohistochemical Assay for Mesothelin Sponsor:   National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 17, 2022 Category: Research Source Type: clinical trials